Drug Trial Radar · NCT05265273
A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis
Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
12
Planned (sponsor's estimate)
Start
Jul 20, 2022
Primary completion
Jun 30, 2027
Study completion Jul 2, 2029
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Mar 3, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the effect of nipocalimab on total serum immunoglobulin G (IgG) in pediatric participants 2 to less than (\<) 18 years of age (globally) and 8 to \<18 years of age (for Unites Stated (US) sites only), the safety and tolerability of treatment with nipocalimab in children and adolescents and to evaluate the pharmacokinetics (PK) of nipocalimab in children and adolescents with generalized myasthenia gravis (gMG) who have an insufficient clinical response to ongoing, stable standard-of-care therapy.
Conditions
- Myasthenia Gravis
Interventions
NipocalimabDrug
Nipocalimab will be administered as an IV infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline in Total Serum Immunoglobulin-G (IgG) LevelsTime frame: Up to 3 years
- Number of Participants with Infectious Adverse Events (AEs)Time frame: Up to 3 years
- Number of Participants with Serious AEs (SAEs)Time frame: Up to 3 years
- Number of Participants with Adverse Events of Special Interests (AESIs)Time frame: Up to 3 years
- Number of Participants with Abnormalities in Clinical Laboratory TestsTime frame: Up to 3 years
- Number of Participants with Abnormalities in Vital SignsTime frame: Up to 3 years
- Number of Participants with Abnormalities in Physical ExaminationTime frame: Up to 3 years
- Serum Concentration of Nipocalimab over TimeTime frame: Up to 3 years
- Clearance (CL) of NipocalimabTime frame: Up to 3 years
- Volume of Distribution (V) of NipocalimabTime frame: Up to 3 years
- Half-life (t1/2) of NipocalimabTime frame: Up to 3 years
- Steady-state Peak Concentration (Cpeak,ss) of NipocalimabTime frame: Up to 3 years
- Steady-state Trough concentration (Ctrough,ss) of NipocalimabTime frame: Up to 3 years
- Steady-state Area Under the Curve (AUCss) of NipocalimabTime frame: Up to 3 years
Locations
19 sites in 4 countries. Site status is shown where the registry gives one.
Phoenix Children's Hospital
Phoenix, Arizona · Recruiting
Childrens Hospital Los Angeles
Los Angeles, California · Completed
Lucile Packard Children's Hospital Stanford
Palo Alto, California · Recruiting
UCSF Benioff Children's Hospital
San Francisco, California · Recruiting
Children's Hospital Colorado
Aurora, Colorado · Recruiting
University of South Florida Morsani Center for Advanced Healthcare
Tampa, Florida · Recruiting
University of Kansas Medical Center
Lawrence, Kansas · Completed
C.S. Mott Children's Hospital
Ann Arbor, Michigan · Recruiting
Penn State Milton S Hershey Medical Ctr
Hershey, Pennsylvania · Recruiting
Childrens Hospital Of Philadelphia
Philadelphia, Pennsylvania · Recruiting
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania · Terminated
Nagano Children's Hospital
Azumino-shi, Japan · Recruiting
Chiba University Hospital
Chiba, Japan · Completed
University of Miyazaki Hospital
Miyazaki, Japan · Recruiting
Hyogo College of Medicine Hospital
Nishinomiya-Shi, Japan · Recruiting
Saitama Prefecture Children's Medical Center
Saitama Shi, Japan · Recruiting
Tokyo Women's Medical University Hospital
Shinjuku-ku, Japan · Recruiting
Leiden University Medical Center
Leiden, Netherlands · Recruiting
Uniwersyteckie Centrum Kliniczne
Gdansk, Poland · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.